Contact|Careers EN|ES About us Technology Platforms Products Investors Newsroom Company Management team Board of directors Company TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is based in Leuven, Belgium, and has operations in Madrid, Spain. Milestones 2016 Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease Termination of Sobi Agreement Six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction Cx601 positive Phase III results to be presented at Digestive Disease Week in the USA Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016 Announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn’s disease patients Submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients Obtains commercial production license for Cx601 Announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress 2015 Completes enrolment of its AlloCSC-01 Phase I/II study in acute myocardial infarction AlloCSC-01 Phase I Data Presented at the Congress of the European Society of Cardiology TiGenix announces Cx601 meets primary endpoint in pivotal Phase III tria TiGenix obtains FDA’s endorsement through Special Protocol Assessment for its Cx601 Phase III registration trial in the US TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition Safety and tolerability of Cx611 confirmed in Phase I sepsis challenge trial USPTO issues key US patent to TiGenix for the use of adipose-derived stromal cells in the treatment of fistulas TiGenix NV successfully places EUR 25 million convertible bonds Tigenix and Lonza sign agreement for the manufacture of Cx601 for Phase III trial in the US European Patent office issues key patent to Tigenix reinforcing Tigenix´s intellectual property of 24 patent families 2014 European Medicines Agency renews Marketing Authorization for ChondroCelect TiGenix announces development plan for Cx611 in early rheumatoid arthritis and severe sepsis TiGenix sells manufacturing facility to PharmaCell TiGenix licenses marketing and distribution of ChondroCelect to Sobi ChondroCelect treats 1000th patient 2013 TiGenix secures Euro 10 million debt financing through Kreos Capital TiGenix raises Euro 12 million through private placement with strategic investor, Grifols TiGenix raises Euro 6.5 million in private placement TiGenix reports positive Phase IIa trial results for Cx611 in refractory rheumatoid arthritis 2012 Cx601﻿ Phase III in perianal fistulas enrolls first patients Cx611 Phase IIa in rheumatoid arthritis completes enrollment National reimbursement ChondroCelect in the Netherlands Cx621﻿ Phase I successfully concluded 2011 TiGenix obtains EUR 5 million financing facility for phase III fistula program in Crohn's disease Positive 5 year data on ChondroCelect published in AJSM TiGenix closes EUR 15.2 mio rights offering TiGenix and Cellerix form European leader in cell therapy National reimbursement ChondroCelect in Belgium 2010 Spin-out of drug discovery platform into Arcarios Commercial launch of ChondroCelect in Europe 2009 ChondroCelect approved by EMA TiGenix receives positive CHMP opinion for ChondroCelect 2007 Initial Public Offering, raising a total of €46m 2000 Incorporation of TiGenix PDF CREATOR You have added 0 page(s) to your PDF. Download your PDF © 2016 TiGenix - Legal - Privacy Policy